Examining expression levels of H2AX in breast cancer
tumor data from The Cancer Genome Atlas, a large National Institutes of Health database containing genetic information about
tumor tissue from more than 11,000 patients, the Roswell Park team found that breast cancer patients
whose tumors had high levels of H2AX had a significantly worse prognosis than those with low levels.